CABA: Cabaletta Bio, Inc. Growth-Adjusted Market Cap to Net Income
The PEG ratio history illustrates the valuation dynamics of Cabaletta Bio, Inc. (CABA), where the metric stands at 0.00. The issuer's revenues are based on the implementation of CART therapies to combat severe autoimmune pathologies. Cabaletta Bio, Inc. (CABA) complies with bio-waste disposal environmental standards and research ethics. Business development relies on organic growth and partnerships with clinics without conducting M&A transactions.
Metric breakdowns and analytics for Cabaletta Bio, Inc. (CABA)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Cabaletta Bio, Inc.|CABA - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio cabalettabio.com|CABA - Company Aggregate Debts|Debts to Book Value Cabaletta Bio, Inc|CABA - Company Long-Term Debts|Company Current Liabilities Cabaletta Bio, Inc.|Quick Ratio cabalettabio.com
- business earnings and investment ratios data:
CABA - Net Profit|Expected Profit Cabaletta Bio, Inc.|CABA - P/E Multiple|Forward P/E Multiple Cabaletta Bio Inc|CABA - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio, Inc|CABA - Operating profit EBITDA|Net earnings per one share for the last twelve months Cabaletta Bio, Inc.|CABA - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months cabalettabio.com|CABA - Net earnings per share growth this year|Projected earnings per share increase next year Cabaletta Bio, Inc.
General company analysis:CABA - Cabaletta Bio Inc.
The PEG ratio compares the P/E multiple with earnings growth rates, allowing for the identification of undervalued assets when the value is below one. The current level of 0.00 regarding the P/E balance and growth reflects the market value of Cabaletta Bio, Inc. (CABA) relative to the potential of the CARTA platform in the race for leadership in CAR-T therapy for autoimmune diseases.
Competing companies
ARGX (argenx N.V.) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (BioNTech Group)|Growth-Adjusted Market Cap to Net Income Abivax (ABVX)|ADMA - Price/Earnings to Growth Ratio|protagonist-inc.com (PTGX) - Price/Earnings to Growth Multiple|Immunovant (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals, Ltd.|Price/Earnings to Growth Multiple GRFS|PEG Multiple Adaptive Biotechnologies Inc.|Price/Earnings to Growth Ratio Celldex Therapeutics (CLDX)|auriniapharma.com - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (BioCryst Pharmaceuticals)|Vera Therapeutics Inc (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Pharma - PEG Multiple|Pharvaris Pharma (PHVS) - Price/Earnings to Growth Multiple|ABCL: PEG Multiple|tourmalinebio.com (TRML) - PEG Multiple|PGEN (Precigen) - PEG Multiple|Price/Earnings to Growth Ratio PHAR|PEG Multiple NKTR|PEG Multiple Upstream Pharma (UPB)|Price/Earnings to Growth Ratio Zenas Biopharma Inc ZBIO|immunome.com - Price/Earnings to Growth Ratio|Gossamer Bio - PEG Multiple|Price to Earnings Adjusted for Growth Rate KalVista Pharma|SEPN (Septerna Corp) - Price/Earnings to Growth Multiple|PVLA: Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple SVRA|RIGL (rigel.com) - Company Value to Earnings Growth Ratio|PEG Multiple ANAB|PEG Multiple Astria Therapeutics Inc (ATXS)|enGene Bio - Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio RAPT|Aerovate - PEG Multiple|ACRS: Price/Earnings to Growth Ratio|KYTX: PEG Multiple|TLSA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Ventyx Bio|Price to Earnings Adjusted for Growth Rate Theratechnologies, Inc THTX|Price/Earnings to Growth Multiple AVTX (Avalo Therapeutics, Inc)|ELDN (eledon.com) - Growth-Adjusted Payback Ratio|PEG Multiple AGEN (Agenus Inc.)|Growth-Adjusted Market Cap to Net Income Climb Bio Inc. (CLYM)|ZURA - Price/Earnings to Growth Ratio|ATYR (aTyr Pharmaceuticals) - Growth-Adjusted P/E Ratio|ADAG: PEG Multiple|Price/Earnings to Growth Multiple Ikena Oncology|Price/Earnings to Growth Multiple STTK|Equillium Bio (EQ) - Growth-Adjusted Market Cap to Net Income|PEG Multiple CNTB|Price/Earnings to Growth Multiple immunic-therapeutics.com IMUX|PEG Multiple ATRA (Atara Bio)|PEG Multiple InflaRx NV IFRX|X4 Pharmaceuticals, Inc. - PEG Multiple|ACET: Price/Earnings to Growth Ratio|CELU: PEG Multiple|INmune Bio Corporation (INMB) - PEG Multiple|Price/Earnings to Growth Ratio Barinthus Biotherapeutics|kezarlifesciences.com - Market Cap to Earnings and Growth Ratio|PEG Multiple SABS|AKTX (Akari Therapeutics PLC) - Growth-Adjusted Payback Ratio|PEG Multiple ENLV (Enlivex Therapeutics Ltd.)|PEG Multiple Q32 Bio Inc QTTB|GOVX - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio EDSA (edesabiotech.com)|iBio (IBIO) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Carisma Therapeutics Inc.|XTLB (XTL Biopharmaceuticals, Ltd.) - PEG Multiple|PEG Multiple Bolt Bio|Price/Earnings to Growth Multiple HCWB (HCW Biologics Inc.)|APVO (aptevotherapeutics.com) - Growth-Adjusted Payback Ratio|PEG Multiple AIM (AIM ImmunoTech)|Growth-Adjusted Market Cap to Net Income Aditxt Inc. (ADTX)|GRI - Price/Earnings to Growth Ratio|XORTX Corp (XRTX) - Price/Earnings to Growth Multiple|Vyome Holdings Inc (HIND) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple revbiosciences.com|Price/Earnings to Growth Multiple INDP|PEG Multiple Scinai Immunotherapeutics Ltd|Price/Earnings to Growth Ratio CalciMedica, Inc. (CALI)|affimed.com - Growth-Adjusted P/E Ratio|PEG Multiple ALLK (Allakos)|HOOKIPA Pharma, Inc. (HOOK) - Price to Earnings Adjusted for Growth Rate|IGM Bio - PEG Multiple|iTeos Therapeutics Inc (ITOS) - Price/Earnings to Growth Multiple|OCEA: PEG Multiple|TC BioPharm Ltd (TCBP) - PEG Multiple|THRD (Third Harmonic Bio) - PEG Multiple
